T he introduction of percutaneous coronary intervention with stent implantation has revolutionized the treatment of patients with obstructive coronary artery disease since the first balloon angioplasty performed by Andreas Grüntzig in 1977. With the widespread use of bare metal stent implantation, the angioplasty-induced complications such as arterial dissection and elastic recoil could be resolved, but this came at the cost of augmented neointimal hyperplasia within the stented vascular segment. This issue prompted the development of drug-eluting stents (DES), which successfully targeted the problem of neointimal overgrowth by sustained release of antiproliferative substances. However, persistence of these drugs resulted in substantial delay of vascular healing, the major pathologic mechanism underlying late and very late stent thrombosis. More recently, in-stent neoatherosclerosis (i.e., progression of atherosclerosis within the stented vascular segment) was identified as additional consequence of delayed vascular healing after DES implantation and associated with late stent failure (1). Ever since the inception of research related to finding solutions to overcome the problem of restenosis, systemic pharmacological therapy became highly attractive (2). Yet, most of these approaches were later abandoned because of unacceptable side effects at drug dosages needed to prevent restenosis (3). In this issue of JACC: Basic to Translational Science, Kee et al. (4) report the results of a preclinical study investigating a novel site-directed pharmacologic approach to reduce in-stent restenosis following stent implantation in a hypercholesterolemic porcine model. They used a combined endovascular ultrasound (EUS) and delivery system to ensure local application of therapeutics from echogenic liposomes (ELIPs) into stented peripheral arteries. The ELIP infusion consisted of an initial nitric oxide (NO) dose to trigger immediate antioxidative and antiplatelet effects and to increase vessel wall permeability for improved delivery of the peroxisome proliferator-activator receptor (PPAR)-g agonist pioglitazone (PGN) coupled to anti-intercellular adhesion molecule (ICAM)directed ELIP. Animals assigned to ELIP payload delivery were randomly allocated to EUS activation or control (absence of EUS activation). Neointimal growth was assessed by intravascular ultrasound imaging and histology 8 weeks after bare-metal stent implantation. To show payload delivery, a separate group of animals underwent balloon dilatation to simulate stent implantation, followed by application of fluorescently labelled ELIP. Intravascular ultrasound imaging showed reduction of neointimal volume in the stented arteries treated by NO-activated and anti-ICAM-1-PGN-ELIP activated by ultrasound compared to the vessels that lacked ultrasound activation. Histologic analysis confirmed reduced neointima formation in the vessels treated with NO-and
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